Category
GLP-1 and GIP
Incretin receptor agonists used in weight management and type 2 diabetes, from single to triple agonists.
RetatrutideSynthetic 39-amino-acid triple GLP-1, GIP, and glucagon receptor agonist from Eli Lilly, not FDA approved, with 20 to 24 percent weight loss in Phase 2 trials.Not FDA approved (Phase 3)SemaglutideSynthetic 31-amino-acid GLP-1 receptor agonist from Novo Nordisk, FDA approved as Ozempic, Wegovy, and Rybelsus, with the broadest evidence base in the class.FDA approved (Ozempic, Wegovy, Rybelsus)TirzepatideSynthetic 39-amino-acid dual GLP-1 and GIP receptor agonist from Eli Lilly, FDA approved as Mounjaro and Zepbound, with superior weight loss to semaglutide.FDA approved (Mounjaro, Zepbound)
Working out a draw?
Enter the vial, the water and the dose; the calculator gives you units on the syringe, doses per vial and days of supply.